LIRILUMAB
UNII S9XDI9W918

Substance Identification & Data

This profile provides standardized clinical and technical data for Lirilumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) S9XDI9W918.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1000676-41-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

S9XDI9W918

CAS Registry Number

1000676-41-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LIRILUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C103820

National Cancer Institute reference terminology for clinical and research data.

INN ID

9415

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

ZZ-164

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lirilumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LIRILUMAB

Common Names & Synonyms

LIRILUMAB [INN]

LIRILUMAB [USAN]

LIRILUMAB [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G4, ANTI-(HUMAN ANTIGEN RECEPTOR KIR (KILLER CELL IMMUNOGLOBULIN-LIKE)) (HUMAN MONOCLONAL ANTI-KIR(CHO) HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL ANTI-KIR(CHO) LIGHT CHAIN, DIMER

SYS